Impact of Utilizing a Composite versus a Symptom-Only Validation Standard in the Development of the Asthma Impairment and Risk Questionnaire

J Asthma Allergy. 2024 Aug 7:17:751-756. doi: 10.2147/JAA.S461524. eCollection 2024.
No abstract available

Grants and funding

This study was supported by AstraZeneca (Wilmington, DE, USA). The Asthma Impairment and Risk Questionnaire (AIRQ) was developed with support from the AstraZeneca PRECISION program.